title: Paclitaxel by 1-hour infusion in combination chemotherapy of stage III non-small cell lung cancer.
abstract: We report our preliminary phase II experience with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) given as a I-hour infusion with cisplatin, etoposide, and concurrent radiotherapy to patients with unresectable stage IIIA or IIIB non-small cell lung cancer. Twenty-three patients have been started on therapy, with 15 thus far completing treatment. Eight of 15 patients have achieved complete or "near complete" responses, and five more patients have had partial responses. No patients experienced disease progression. The combined-modality regimen was well tolerated, with the exception of grade 3 or 4 esophagitis, which usually occurred during the last 2 weeks of radiation therapy (eight patients). It is hoped the results of these and other studies will help clarify the role of paclitaxel in multimodality therapy for lung cancer.
authors.affiliation: Department of Medical Oncology, Sarah Cannon-Minnie Pearl Cancer Center, Nashville, TN 37203, USA.
authors.forename: F A
authors.initials: FA
authors.lastname: Greco
authors.forename: S L
authors.initials: SL
authors.lastname: Stroup
authors.forename: J D
authors.initials: JD
authors.lastname: Hainsworth
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000532:radiotherapy; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D004941:Esophagitis / Q000209:etiology; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D007275:Injections, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D011878:Radiotherapy / Q000009:adverse effects; D012074:Remission Induction
chemical_list: D005047:Etoposide; D017239:Paclitaxel; D002945:Cisplatin